Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Gilead Sciences (DE:GIS)
XETRA:GIS
Holding DE:GIS?
Track your performance easily
Earnings Data
Report Date
Feb 11, 2025After Close Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
€1.65Last Year’s EPS
€1.65Same Quarter Last Year
Moderate Buy
Based on 26 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 06, 2024
|% Change Since: 5.40%
|Next Earnings Date:Feb 11, 2025
Earnings Call Sentiment|Positive
The earnings call presented a generally positive outlook with strong revenue growth across key segments like HIV and oncology. The company showed progress in its pipeline with promising drug candidates and improved financial guidance for 2024. However, there were challenges in the cell therapy segment and a significant impairment charge impacting financial results.Company Guidance
During Gilead's Q3 2024 earnings call, the company reported strong operational performance, with total product sales, excluding Veklury, reaching $6.8 billion, marking a 7% year-over-year increase. Including Veklury, total sales were $7.5 billion, also reflecting a 7% increase. Gilead highlighted a robust 9% growth in HIV sales, with Biktarvy sales rising by 13% year-over-year. The company increased its full-year guidance across several metrics, including revenue, non-GAAP gross margin, operating income, and EPS. Additionally, Gilead noted significant progress in its virology programs, particularly with lenacapavir, which received a breakthrough therapy designation from the FDA for HIV prevention. The oncology segment also showed promising developments, with Trodelvy's sales up 17% year-over-year, and the company shared encouraging data from its anito-cel program for multiple myeloma. Overall, Gilead demonstrated strong commercial and clinical execution, with a continued focus on expense management and strategic resource allocation.Strong Revenue Growth
Total product sales excluding Veklury were $6.8 billion, up 7% year-over-year. Including Veklury, total product sales were $7.5 billion, also up 7% year-over-year.
HIV Segment Performance
HIV sales were up 9% year-over-year, with Biktarvy sales increasing by 13% year-over-year. The full-year HIV growth expectation has been increased to 5%.
Positive Pipeline Developments
FDA granted breakthrough therapy designation for lenacapavir for HIV prevention. Lenacapavir showed 100% efficacy in the PURPOSE 1 trial for HIV prevention, and the PURPOSE 2 trial was stopped early due to efficacy.
Oncology Advances
Trodelvy sales were up 17% year-over-year. Exciting preliminary data from the IMAGINE-1 study for anito-cel for multiple myeloma was shared, demonstrating a 95% objective response rate.
Improved Financial Guidance
2024 guidance increased across almost every metric, including revenue and non-GAAP gross margin, operating income, and EPS. Full-year Veklury revenue guidance raised to $1.8 billion.
---
DE:GIS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
DE:GIS Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 06, 2024 | €84.60 | €89.19 | +5.43% |
| Aug 08, 2024 | €67.93 | €66.20 | -2.55% |
| Apr 25, 2024 | €59.47 | €59.52 | +0.08% |
| Feb 06, 2024 | €69.42 | €66.83 | -3.74% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Gilead Sciences (DE:GIS) report earnings?
Gilead Sciences (DE:GIS) is schdueled to report earning on Feb 11, 2025, After Close Not Confirmed.
What is Gilead Sciences (DE:GIS) earnings time?
Gilead Sciences (DE:GIS) earnings time is at Feb 11, 2025, After Close Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Gilead Sciences stock?
The P/E ratio of Gilead Sciences is 990.8.
What is DE:GIS EPS forecast?
DE:GIS EPS forecast for the fiscal quarter 2024 (Q4) is €1.65.
---